Dr. Aung Naing, MD

Dr. Naing practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Naing's NPI, 1104837590, was assigned on August 10, 2006. Dr. Naing graduated from Hacettepe University FOM in 1997. Dr. Naing holds Texas license M5398.

Dr. Naing's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Naing's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Naing practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Naing's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Naing is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Naing's licenses on file in 11 states: Texas, California, Florida, Tennessee, Mississippi, Oklahoma, Washington, Alabama, Arizona, Georgia and Louisiana.

Dmand AI lists breast cancer, colorectal cancer, fluid and electrolyte imbalances, lung cancer and prostate cancer among the conditions Dr. Naing treats.

CMS data shows 449 Medicare services from Dr. Naing across 6 procedure codes in 2024, for 192 Medicare patients. Medicare paid $47,673 for them.

CMS counts 192 Medicare patients who saw Dr. Naing in 2024. The largest group is 65 to 74, with 130 patients. 75% of them have high blood pressure, and 66% have high cholesterol. 6% are also on Medicaid. Their average risk score is 3.36, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Naing's median patient age at 67, with 51% women.

In 2024, Dr. Naing wrote 49 Medicare Part D claims for 20 patients. 98% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $404 in total drug cost. In 2020, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Naing for performance year 2024, reported as part of a group. Dr. Naing accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Naing as offering telehealth.

Dmand AI links 213 papers to Dr. Naing, published from 2009 to 2025. 2021 was the busiest year, with 15. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents and Antibodies, Monoclonal, Humanized. Dr. Naing has published most often in J Immunother Cancer. Dr. Naing's most frequent co-authors are Apostolia Maria Tsimberidou, MD, PhD, Sarina Anne Piha-Paul, MD and Filip Janku, MD, PhD.

Dmand AI links Dr. Naing to 28 clinical trials, 19 of them phase 1 studies. 7 are still active or recruiting. Conditions studied include Neoplasm Metastasis, Kidney Neoplasms and Carcinoma, Renal Cell. M.D. Anderson Cancer Center sponsors the most, 15.

CMS Open Payments shows 41 general payments to Dr. Naing from 8 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 61% of the total. Novartis Pharmaceuticals Corporation paid the most, $9,577. It also lists 12 research payments totaling $906,616 from 2018 to 2024.

Dr. Naing graduated from Hacettepe University FOM in 1997. Dr. Naing is a member of ASCO.

Dr. Naing is in network with 5 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 4. Check the plan with the practice before a visit.